TIGAN(R) (TRIMETHOBENZAMIDE HYDROCHLORIDE)

FDA Drug Profile — TIGAN(R) (TRIMETHOBENZAMIDE HYDROCHLORIDE)

TIGAN(R) (TRIMETHOBENZAMIDE HYDROCHLORIDE) is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including TIGAN(R) (TRIMETHOBENZAMIDE HYDROCHLORIDE). Available dosage form: injection.

Drug details

Generic Name
TIGAN(R) (TRIMETHOBENZAMIDE HYDROCHLORIDE)
Brand Names
TIGAN(R) (TRIMETHOBENZAMIDE HYDROCHLORIDE)
Application Number
NDA017530
Sponsor
HF Acquisition Co LLC, DBA HealthFirst
NDC Codes
1
Dosage Forms
INJECTION
Routes
INTRAMUSCULAR
Active Ingredients
TRIMETHOBENZAMIDE HYDROCHLORIDE

Indications and Usage

INDICATIONS Tigan® is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.

Warnings

WARNINGS Tigan® may produce drowsiness. Patients should not operate motor vehicles or other dangerous machinery until their individual responses have been determined. Usage in Pregnancy Trimethobenzamide hydrochloride was studied in reproduction experiments in rats and rabbits and no teratogenicity was suggested. The only effects observed were an increased percentage of embryonic resorptions or stillborn pups in rats administered 20 mg and 100 mg/kg and increased resorptions in rabbits receiving 100 mg/kg. In each study these adverse effects were attributed to one or two dams. The relevance to humans is not known. Since there is no adequate experience in pregnant or lactating women who have received this drug, safety in pregnancy or in nursing mothers has not been established. Usage with Alcohol Concomitant use of alcohol with Tigan® may result in an adverse drug interaction.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.